Cellular Biomedicine Group, Inc.
CBMG
CBMG was delisted on the 19th of February, 2021.
0 hedge funds and large institutions have $0 invested in Cellular Biomedicine Group, Inc. in 2021 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 66 closing their positions.
100% less funds holding
Funds holding: 67 → 0 (-67)
100% less capital invested
Capital invested by funds: $80M → $0 (-$80M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 66
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$16.1M |
| 2 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$4.33M |
| 3 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
-$4.32M |
| 4 |
GCL
Glazer Capital LLC
New York
|
-$4.27M |
| 5 |
State Street
Boston,
Massachusetts
|
-$4.17M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Barclays
London,
United Kingdom
| – | -$73K | -3,976 | Closed |
|
|
TRCT
52
Tower Research Capital (TRC)
New York
| – | -$54K | -2,948 | Closed |
|
53
Citigroup
New York
| – | -$47K | -2,580 | Closed |
|
54
BNP Paribas Financial Markets
Paris,
France
| – | -$47.3K | -2,571 | Closed |
|
55
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$34K | -1,875 | Closed |
|
56
Legal & General Group
London,
United Kingdom
| – | -$25K | -1,370 | Closed |
|
|
AIP
57
Ameritas Investment Partners
Lincoln,
Nebraska
| – | -$18K | -958 | Closed |
|
58
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$11K | -605 | Closed |
|
|
CCA
59
Childress Capital Advisors
Houston,
Texas
| – | -$3K | -144 | Closed |
|
60
Osaic Holdings
Scottsdale,
Arizona
| – | -$2K | -100 | Closed |
|
|
WOC
61
West Oak Capital
Westlake Village,
California
| – | -$2K | -100 | Closed |
|
|
PA
62
Parallel Advisors
San Francisco,
California
| – | -$1K | -73 | Closed |
|
|
APA
63
American Portfolios Advisors
Holbrook,
New York
| – | -$221 | -12 | Closed |
|
CBMG Hedge Fund Activity: Q1 2021 in Review
0 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Cellular Biomedicine Group, Inc. (CBMG) for Q1 2021, worth a combined $0 — down 100% from $80M a quarter earlier.
Sellers outnumbered buyers: 66 funds closed out of CBMG and 0 opened new positions — a net loss of 66 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was BlackRock, exiting entirely with an estimated $16.1M sold.
- 0 institutional investors held Cellular Biomedicine Group, Inc. (CBMG) as of Q1 2021, down from 67 in Q4 2020.
- Funds reported $0 of Cellular Biomedicine Group, Inc. stock for Q1 2021, down 100% quarter-over-quarter.
- 0 funds opened new Cellular Biomedicine Group, Inc. positions in Q1 2021 and 66 closed out, a net change of -66 holders.
- The largest Cellular Biomedicine Group, Inc. seller in Q1 2021 was BlackRock, an estimated $16.1M sold.
Based on aggregated 13F filings for Q1 2021.